CD34, Fc Fusion, Avi-Tag Recombinant

Only %1 left
Catalog #
101812
As low as $300 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human CD34 (also known as Hematopoietic progenitor cell antigen CD34), encompassing amino acids 32-290. The C-terminus of this construct is fused with the Fc fragment of a human IgG1 followed by an Avi-Tag™. The recombinant protein was affinity purified.

Synonyms
Hematopoietic progenitor cell antigen CD34, CD34
Product Info
Storage and Usage
Citations
Species
Human
Construct
CD34 (32-290-Fc(IgG1)-Avi)
Host Species/Expression System
HEK293
Purity

≥90%

Format

Aqueous buffer solution.

Formulation

8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

MW
56 kDa + glycans
Amino Acids
32-290
Glycosylation
This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank #
NM_001773
UniProt #
P28906
Tag(s)
C-terminal Avi-Tag™
Background

CD34 (Cluster of Differentiation-34) is a single-pass transmembrane hosphor-glycoprotein and a stem cell antigen. It is a receptor for L-Selectin (CD62L) and CrkL ligands, as well as E- and P-Selectin in the bone marrow extracellular matrix. It can act both as a cell adhesion molecule and as an adhesion blocking molecule against mast cells, dendritic precursors and eosinophils. CD34 is often expressed on the surface of hematopoietic stem cells (HSC) and is commonly used for positive selection and identification of CD34+ cells for stem cell therapy. More recently CD34 has been identified as a potential predictor of neoadjuvant chemotherapy efficacy in cervical cancer patients. Infusion of CD34+ cells has been applied in the treatment of spinal cord injury, liver cirrhosis and vascular disease, in addition to hematological malignancies.